[Origin and nature of the neutralizing immune response against therapeutic factor VIII].
Origine et nature de la réponse immunitaire neutralisante contre le facteur VIII thérapeutique.
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
10
2020
Statut:
ppublish
Résumé
The use of therapeutic proteins induces in some patients the appearance of neutralizing antibodies. This is the case of pro-coagulant factor VIII (FVIII) used in patients with hemophilia A. Several parameters related to the protein itself, to the type of pathology or to the patients, condition the immunogenicity of a therapeutic protein. Understanding these parameters would help to anticipate or prevent the development of neutralizing antibodies. In the case of FVIII, we propose that the development of neutralizing antibodies does not result from an unpredicted immune response but rather from the inability of the patient's organism to develop an anti-inflammatory or regulatory response. Origine et nature de la réponse immunitaire neutralisante contre le facteur VIII thérapeutique. L’utilisation de protéines thérapeutiques se heurte, chez certains patients, à l’apparition d’anticorps neutralisants. C’est le cas, par exemple, du facteur VIII pro-coagulant qui est utilisé pour traiter les patients atteints d’hémophilie A. Plusieurs paramètres, liés à la protéine elle-même, au type de pathologie ou aux patients, conditionnent l’immunogénicité d’une protéine thérapeutique. Les comprendre permettrait d’anticiper ou de prévenir la survenue d’anticorps neutralisants. Nous proposons dans cette revue de montrer que, dans le cas du facteur VIII, la survenue de ces anticorps neutralisants ne résulte pas d’une réponse immunitaire inopinée, mais plutôt de l’incapacité de l’organisme des patients à développer une réponse anti-inflammatoire ou régulatrice.
Autres résumés
Type: Publisher
(fre)
Origine et nature de la réponse immunitaire neutralisante contre le facteur VIII thérapeutique.
Identifiants
pubmed: 32356710
doi: 10.1051/medsci/2020060
pii: msc190268
doi:
Substances chimiques
Antibodies, Neutralizing
0
F8 protein, human
839MOZ74GK
Factor VIII
9001-27-8
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
341-347Informations de copyright
© 2020 médecine/sciences – Inserm.
Références
Lacroix-Desmazes S , Navarrete A-M , André S , et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008 ; 112 : 240–249.
Ing M , Gupta N , Teyssandier M , et al. Immunogenicity of long-lasting recombinant factor VIII products. Cell Immunol 2016 ; 301 : 40–48.
Teyssandier M , André S , Gupta N , et al. Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro. Haemophilia 2013 ; 19 : 399–402.
Pfistershammer K , Stöckl J , Siekmann J , et al. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006 ; 96 : 309–316.
Skupsky J , Zhang A-H , Su Y , et al. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood 2009 ; 114 : 4741–4748.
Meeks SL , Cox CL , Healey JF , et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 2012 ; 120 : 2512–2520.
Gangadharan B , Delignat S , Ollivier V , et al. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A. J Thromb Haemost 2014 ; 12 : 2065–2069.
Lai JD , Moorehead PC , Sponagle K , et al. Concurrent influenza vaccination reduces anti-FVIII antibody responses in hemophilia A mice via chemotactic antigen competition. Blood 2016 ; 127 : 3439–3449.
Platokouki H , Fischer K , Gouw SC , et al. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia 2018 ; 24 : 283–290.
Dimitrov JD , Dasgupta S , Navarrete A-M , et al. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. Blood 2010 ; 115 : 2682–2685.
Peyron I , Dimitrov JD , Delignat S , et al. Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice. Haemoph Off J World Fed Hemoph 2015 ; 21 : e94–e98.
Kurnik K , Bidlingmaier C , Engl W , et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010 ; 16 : 256–262.
Auerswald G , Bidlingmaier C , Kurnik K . Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience. Haemophilia 2012 ; 18 : e18–e20.
Sakaguchi S , Vignali DAA , Rudensky AY , et al. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013 ; 13 : 461–467.
Hu G-L , Okita DK , Diethelm-Okita BM , et al. Recognition of coagulation factor VIII by CD4
Reding MT , Wu H , Krampf M , et al. Sensitization of CD4
Meunier S , Menier C , Marcon E , et al. CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. Blood Adv 2017 ; 1 : 1842–1847.
Delluc S , Ravot G , Maillere B . Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J 2011 ; 25 : 2040–2048.
Delluc S , Ravot G , Maillere B . Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010 ; 116 : 4542–4545.
Pinto S , Michel C , Schmidt-Glenewinkel H , et al. Overlapping gene coexpression patterns in human medullary thymic epithelial cells generate self-antigen diversity. Proc Natl Acad Sci U S A 2013 ; 110 : E3497–E3505.
Hu GL , Okita DK , Diethelm-Okita BM , et al. Recognition of coagulation factor VIII by CD4
Kamaté C , Lenting PJ , Van Den Berg HM , et al. Depletion of CD4
Algiman M , Dietrich G , Nydegger UE , et al. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992 ; 89 : 3795–3799.
Whelan SFJ , Hofbauer CJ , Horling FM , et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013 ; 121 : 1039–1048.
Hofbauer CJ , Whelan SFJ , Hirschler M , et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2015 ; 125 : 1180–1188.
Gilles JG , Saint-Remy JM . Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994 ; 94 : 1496–1505.
Sakurai Y , Shima M , Tanaka I , et al. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors. Haematologica 2004 ; 89 : 696–703.
Oldenburg J , El-Maarri O , Schwaab R . Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002 ; 8 : 23–29.
Peyvandi F , Mannucci PM , Garagiola I , et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016 ; 374 : 2054–2064.
Gouw SC , van der Bom JG . Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007 ; 109 : 4648–4654.
Hay CRM , Palmer B , Chalmers E , et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011 ; 117 : 6367–6370.
Jagger AT , Shimojima Y , Goronzy JJ , et al. T regulatory cells and the immune aging process. Gerontology 2014 ; 60 : 130–137.
Pautard B D’oiron R, Li Thiao Te V, et al. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells. J. Thromb Haemost 2011 ; 9 : 1163–1170.
Gilles JG , Desqueper B , Lenk H , et al. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996 ; 97 : 1382–1388.
Repesse Y , Peyron I , Dimitrov JD , et al. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica 2013 ; 98 : 1650–1655.
Matino D , Gargaro M , Santagostino E , et al. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest 2015 ; 125 : 3766–3781.
Moghimi B , Sack BK , Nayak S , et al. Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 2011 ; 9 : 1524–1533.
Hassan S , Fijnvandraat K , van der Bom JG , et al. Preventing or eradicating factor VIII antibody formation in patients with hemophilia A: what can we learn from other disorders?. Semin Thromb Hemost 2018 ; 44 : 531–543.